Advertisement
Singapore markets closed
  • Straits Times Index

    3,297.55
    -26.98 (-0.81%)
     
  • Nikkei

    38,814.56
    +94.09 (+0.24%)
     
  • Hang Seng

    17,941.78
    -170.85 (-0.94%)
     
  • FTSE 100

    8,146.86
    -16.81 (-0.21%)
     
  • Bitcoin USD

    65,998.95
    -872.57 (-1.30%)
     
  • CMC Crypto 200

    1,400.42
    -17.45 (-1.21%)
     
  • S&P 500

    5,431.60
    -2.14 (-0.04%)
     
  • Dow

    38,589.16
    -57.94 (-0.15%)
     
  • Nasdaq

    17,688.88
    +21.32 (+0.12%)
     
  • Gold

    2,348.40
    +30.40 (+1.31%)
     
  • Crude Oil

    78.49
    -0.13 (-0.17%)
     
  • 10-Yr Bond

    4.2130
    -0.0250 (-0.59%)
     
  • FTSE Bursa Malaysia

    1,607.32
    -2.85 (-0.18%)
     
  • Jakarta Composite Index

    6,734.83
    -96.73 (-1.42%)
     
  • PSE Index

    6,383.70
    -7.13 (-0.11%)
     

CompuGroup Medical SE KGaA First Quarter 2024 Earnings: EPS: €0.35 (vs €0.28 in 1Q 2023)

CompuGroup Medical SE KGaA (ETR:COP) First Quarter 2024 Results

Key Financial Results

  • Revenue: €299.9m (flat on 1Q 2023).

  • Net income: €18.5m (up 29% from 1Q 2023).

  • Profit margin: 6.2% (up from 4.8% in 1Q 2023).

  • EPS: €0.35 (up from €0.28 in 1Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

CompuGroup Medical SE KGaA Earnings Insights

Looking ahead, revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in Europe.

Performance of the market in Germany.

The company's shares are down 1.4% from a week ago.

Risk Analysis

You still need to take note of risks, for example - CompuGroup Medical SE KGaA has 2 warning signs we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.